AbbVie’s Aquipta (atogepant) Receives EC’s Approval for the Preventive Treatment of Migraine in Adults
Shots:
- The EC has approved Aquipta (CGRP receptor antagonist) for the prophylaxis of migraine in adults who have ≥4 migraine days per month. The approval was based on the 2 P-III studies (PROGRESS) & (ADVANCE) evaluating Aquipta (60mg, qd) vs PBO in 778 & 910 patients
- Both studies met their 1EPs i.e., reduction in mean monthly migraine days vs PBO, improvements were observed in all 2EPs with Aquipta (60mg, qd). In the (PROGRESS) & (ADVANCE) study, a reduction in the changes from baseline in MMDs of 6.8 vs 5.1 days & 4.1 vs 2.5 days; 40% vs 27% & 59% vs 29% achieved a 50% reduction in MMDs, respectively
- The therapy was approved in the US for chronic & episodic migraine and in Canada for episodic migraine under the brand name Qulipta
Ref: PR Newswire | Image: AbbVie
Related News:- AbbVie Receive EMA’s CHMP Positive Opinion Recommending Approval of Atogepant for the Preventive Treatment of Adults with Migraine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
